Informations générales (source: ClinicalTrials.gov)
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (ARCHER II)
Interventional
Phase 3
Annexon, Inc. (Voir sur ClinicalTrials)
juillet 2024
octobre 2027
13 mai 2025
The primary purpose of the study is to determine if IVT injections of ANX007 every month
reduce vision loss in participants with GA secondary to age-related macular degeneration
(AMD).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU Dijon Bourgogne - Hôpital François Mitterrand - 21079 - Dijon Cedex - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and
confirmed by the independent Central Reading Center.
- Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and
confirmed by the independent Central Reading Center.
- Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod
dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil
maculopathy) in either eye.
NOTE: Other protocol-defined inclusion and exclusion criteria may apply.